HLA-C and KIR permutations influence chronic obstructive pulmonary disease risk

Takudzwa Mkorombindo, … , Frank C. Sciurba, Steven R. Duncan


A role for hereditary influences in the susceptibility for chronic obstructive pulmonary disease (COPD) is widely recognized. Cytotoxic lymphocytes are implicated in COPD pathogenesis, and functions of these leukocytes are modulated by interactions between their killer-cell immunoglobulin-like receptors (KIR) and human leukocyte antigen (HLA)-Class I molecules on target cells. We hypothesized HLA-Class I and KIR inheritance affect risks for COPD. HLA-Class I alleles and KIR genotypes were defined by candidate gene analyses in multiple cohorts of COPD patients (total n=392) and control smokers with normal spirometry (total n=342). Compared to controls, COPD patients had over-representations of HLA-C*07 and activating KIR2DS1, with under-representations of HLA-C*12. Particular HLA-KIR permutations were synergistic; e.g. the presence of HLA-C*07 + KIR2DS1 vs. HLA-C*07null + KIR2DS1null + HLA-C12 was associated with COPD, especially among HLA-C1 allotype homozygotes (OR=18.5, 95%CI=3.7-90.9, p<0.0001). Cytotoxicity of COPD lymphocytes was more enhanced by KIR stimulation than those of controls (p=0.005) and was correlated with lung function (r=0.44, p=0.004). These data show HLA-C and KIR polymorphisms strongly influence COPD susceptibility and highlight the importance of lymphocyte-mediated cytotoxicity in COPD pathogenesis. Findings here also indicate HLA-KIR typing could stratify at-risk patients and raise possibilities HLA-KIR axis modulation may have therapeutic potential.
HLA-C AND KIR PERMUTATIONS INFLUENCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE RISK

Takudzwa Mkorombindo, M.D., Thi K. Tran-Nguyen, Ph.D., Kaiyu Yuan, M.D., Yingze Zhang, Ph.D., Jianmin Xue, M.D., Gerald J. Criner, M.D., Young-il Kim, Ph.D., Joseph M. Pilewski, M.D., Amit Gaggar, M.D., Michael H. Cho, M.D., Frank C. Sciurba, M.D., Steven R. Duncan, M.D.

1Division of Pulmonary, Allergy & Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama
2Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
3Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania
4Division of Preventive Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama
5Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts

Corresponding Author: Steven R. Duncan, M.D.
Address: 1900 University BLVD, THT 513C
Birmingham, Alabama USA 35294
Email: srduncan@uabmc.edu
Phone: +1 (205) 934-5017

Conflict of Interest Statement: The authors have declared that no conflict of interest exists.
Key Words: NK cells, Genetic Variation, Complex traits

Author Contributions: All authors contributed to the writing and/or editing of this manuscript. Conception and design: SRD, YZ, and FCS; acquisition of data for the work: TM, TKTN, KY, YZ, JX, JMP, GC; analysis and interpretation: TM, YZ, YK, SRD; and drafting the manuscript for important intellectual content: TM, AG, YK, MHC, SRD

Funding Support: U.S. N.I.H. grants HL107172 (Duncan), HL084948 (Duncan), and HL084948 (Sciurba)

Running Head: HLA and KIR Interactions in Smokers

Word Count: 3493
ABSTRACT

A role for hereditary influences in the susceptibility for chronic obstructive pulmonary disease (COPD) is widely recognized. Cytotoxic lymphocytes are implicated in COPD pathogenesis, and functions of these leukocytes are modulated by interactions between their killer-cell immunoglobulin-like receptors (KIR) and human leukocyte antigen (HLA)-Class I molecules on target cells. We hypothesized HLA-Class I and KIR inheritance affect risks for COPD. HLA-Class I alleles and KIR genotypes were defined by candidate gene analyses in multiple cohorts of COPD patients (total n=392) and control smokers with normal spirometry (total n=342). Compared to controls, COPD patients had over-representations of HLA-C*07 and activating KIR2DS1, with under-representations of HLA-C*12. Particular HLA-KIR permutations were synergistic; e.g. the presence of HLA-C*07 + KIR2DS1 + HLA-C12null vs. HLA-C12null + KIR2DS1null + HLA-C12 was associated with COPD, especially among HLA-C1 allotype homozygotes (OR=18.5, 95%CI=3.7-90.9, p<0.0001). Cytotoxicity of COPD lymphocytes was more enhanced by KIR stimulation than those of controls (p=0.005) and was correlated with lung function (r=0.44, p=0.004). These data show HLA-C and KIR polymorphisms strongly influence COPD susceptibility and highlight the importance of lymphocyte-mediated cytotoxicity in COPD pathogenesis. Findings here also indicate HLA-KIR typing could stratify at-risk patients and raise possibilities HLA-KIR axis modulation may have therapeutic potential.

Abstract Word Count=200
INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is a leading cause of death worldwide, and the prevalence, cumulative morbidity, and public health burden of this syndrome continue to increase (1). While tobacco smoking is the major predisposing factor for COPD in industrialized societies, genetic modifiers also appear important since only a minority of heavy smokers develop clinically significant lung disease, and familial clustering of cases is prominent (2,3). Some genetic determinants of COPD have been identified by genome-wide association studies (GWAS) or other methods (3-5). However, the functional correlates of many disease-associated polymorphisms remain unknown, and variants reported to date account for only a small portion of COPD heritability (3,5,6). A better understanding of mechanisms that promote the development and/or progression of COPD could have significant, actionable importance.

Although many details of COPD pathogenesis remain enigmatic, the participation of cytotoxic lymphocytes (i.e., NK cells and some T-cell subpopulations) in the causality and/or progression of this disease is widely acknowledged (6,7). Human leukocyte antigens (HLA) are the strongest known genetic determinants of immunologically-mediated diseases and key regulators of cytotoxic lymphocytes (8). In particular, HLA-Class I molecules mediate antigen presentation to cytotoxic CD8 T-cells (9) and are cognate ligands for killer-cell immunoglobulin-like receptors (KIR) on the surfaces of NK cells (10-12). NK cells can be either stimulated or inhibited by KIR crosslinking, depending on the structural characteristics of these receptors (13). Structure is also reflected in KIR nomenclature: the number of their extracellular domains (either two or three) are designated as 2D or 3D, respectively, and the defining features of their cytoplasmic tails are denoted as either short (S) (which tend to be stimulatory) or long (L) (which are mostly inhibitory) (13). Hence, HLA engagements with various KIR can either stimulate or inhibit effector functions of NK cells and cytotoxic lymphocytes, depending on the relatively expressions of particular KIR (10-12). Furthermore, specific HLA-KIR combinations modify the risks of developing several immunological syndromes, including diverse autoimmune diseases, malignancies, and infections (11,12,14).
We initially hypothesized HLA-Class I polymorphisms may be important in COPD pathogenesis, similar to findings in other immune disorders (8,9). We further presupposed disease-associated HLA biases would be most evident in focused candidate gene assays that compared extreme-of-phenotype cases, i.e., COPD patients with severe expiratory airflow vs. control subjects with extensive smoking histories, but normal spirometry.

Early findings of these assays that showed HLA-Class I polymorphisms at the HLA-C locus are linked to COPD prompted us to further examine the KIR that could interact with those alleles (10-14). In addition, since some actions of the HLA-KIR axis are known, it also seemed possible these genetic findings might be amenable to additional corroboration by *in vitro* functional assays.

The results of these studies show distinct HLA-C and KIR frequencies are biased in COPD patients. In addition, the pathophysiologic effects of this phenomenon appear largely mediated via cytotoxic lymphocytes, and NK cells especially.
RESULTS

**Discovery Cohort Subjects:** Smoking exposures and ages of the COPD subjects were slightly, but significantly, less than the smoke controls (SC) (participants who had at least 30 pack-years of cigarette smoking, but normal spirometry) (Online Supplement Table 1). Ninety-seven percent (97%) of the COPD subjects had severe or very severe lung disease (GOLD Stages 3 or 4) (1).

**Discovery Cohort HLA-Class I Allele Prevalence:** An initial pilot trial comparing HLA-Class I alleles among the 170 COPD lung transplant subjects vs. the first evaluable cohort of SC subjects (n=81) indicated intergroup differences were greatest at the HLA-C locus, especially at *HLA-C*07 (Online Supplement Table 2). An over-representation of HLA-B*07 in the COPD was less significant (Online Supplement Table 2), and a likely feature of the interdependence of that allele with *HLA-C*07, given that these two alleles are in strong linkage disequilibrium (LD) (i.e., an association of alleles at neighboring loci that exceeds purely random cosegregation) (15). *HLA-C*07 is also more prevalent in the general population (16) and hence, was presumed to have greater potential biological/clinical importance. Furthermore, there were no significant under-representations (a potentially “protective” polymorphism) of any HLA-A or HLA-B allele in the COPD, whereas there was a trend for decreased *HLA-C*12 prevalence among the pilot trial SC subjects (Online Supplement Table 2). Given these data, assays in the remaining subjects focused on definitions of HLA-C alleles.

The most significant findings in the analyses of the total discovery cohort (Online Supplement Table 3) were an over-representation among the COPD of *HLA-C*07 (OR=2.32, 95%CI=1.51-3.58, p=0.0001) with an under-representation in these participants of *HLA-C*12 (OR=0.45, 95%CI=0.25-0.95, p=0.03).

**Validation Cohort Analyses:** SC in the validation cohort were younger than the comparison COPD subjects, whereas smoking exposures were not significantly different between these subpopulations (Online Supplement Table 4). Validation COPD subjects had significantly less severe lung disease
than the initial discovery cohort COPD transplant patients, as evidenced by percentages of predicted values for forced expiratory volume in one second (FEV$_1$%p) of 36.3±22.0 vs. 25.2±11.2, respectively (p<0.0001) (Online Supplement Tables 1 and 4).

The most striking intergroup differences of HLA-C allele frequencies within the validation cohort were [again] over-representations of HLA-C*07 (OR=1.82, 95%CI=1.21-2.75, p=0.004) and under-representations of HLA-C*12 (OR=0.50, 95%CI=0.26-0.97, p<0.04) among the COPD participants.

**HLA-C Analyses of All Subjects:** Table 1 details the demographic and clinical characteristics of the aggregate (all discovery and validation) subjects.

HLA-C allele analyses of this cumulative study population again showed HLA-C*07 and HLA-C*12 had the strongest associations with COPD (Table 2, Figures 1A and 1B). COPD prevalence among HLA-C*07 + HLA-C*12 heterozygotes (46%) tended to be intermediate between subjects with only HLA-C*07 (62%) or only HLA-C*12 (35%), but the difference did not reach significance (p=0.1). HLA-C*07 copy number did not alter COPD prevalence (61% vs. 63%, for the 315 HLA-C*07 heterozygotes and 81 homozygotes, respectively, p=0.7). Only one subject, a SC, was homozygous for HLA-C*12. Expiratory airflow obstruction was too strongly co-dependent with radiographic emphysema in the COPD patients to allow meaningful assessments of HLA-emphysema associations in that subpopulation (FEV1%p vs. emphysema score p<0.0001). Emphysema was also present in 31% of SC, and neither HLA-C*07 or HLA-C*12 was significantly associated with the presence or severity of this abnormality (data not shown).

**KIR Genotypes:** A pilot analysis of KIR genotypes known to engage HLA-C alleles (11-14) indicated the greatest intergroup difference among them was an over-representation of activating KIR2DS1 in the COPD subjects (Online Supplement Figure 1). KIR2DS1 assays were performed in 349 COPD and 342 SC specimens with sufficient DNA. These assays confirmed KIR2DS1 was more prevalent in COPD than among SC (49.3% vs. 29.8%, respectively, OR=1.65, 95%CI=1.21-2.26, p=0.0017).
KIR2DS1 also had interactive effects with both HLA-C*07 and HLA-C*12. The concomitant presence of KIR2DS1 among subjects with HLA-C*07 multiplied risks for COPD (Figure 2A). Conversely, the presence of KIR2DS1 seemed to largely negate COPD “protection” associated with HLA-C*12 (Figure 2B). Given the potential complexities of these interactions, we compared COPD prevalence among the subpopulation with the highest disease risk (HLA-C*07 + KIR2DS1 + HLA-C*12null) vs. those with the least risk (HLA-C*12 + HLA-C*07null + KIR2DS1null) and again found strong epistatic (multiplicative) effects among these genetic elements (Figure 2C).

Functional effects of HLA-KIR interactions can vary highly depending on which of the dimorphic HLA-C allotypes, determined by polymorphisms at positions 77 and 80 of the C-terminal heavy chain, are involved in that engagement (10-14). HLA-C1 allotypes (serine 77, asparagine 80) include HLA-C*07 and HLA-C*12, whereas HLA-C2 allotypes have asparagine in position 77, and lysine at 80 (Table 2). Because these HLA-C allotypes may exert profoundly different actions, and/or have distinct disease distributions (10-14), we examined COPD associations with the two HLA-C allotypes. COPD was much more prevalent in C1 homozygotes (59%) than among HLA-C2 homozygotes (38.8%) (Figure 3A). Even more striking, the interactive effects of HLA alleles C*07 and C*12 with KIR2DS1 were also highly modified among the different HLA-C allotypes, with the strongest epistasis evident in C1 allotype homozygotes (Figures 3B and 3C).

**Peripheral Blood mononuclear cells (PBMNC) Phenotypes:** The apparent associations of COPD with the HLA-KIR axis, and the presumed importance of these genetic interactions in cytotoxic lymphocyte functions, prompted further studies to investigate these cells in the subject subpopulations. We first found the proportions of cytotoxic CD8 T-cells were similar in both subject groups (Figure 4A). Similarly, the proportion of PBMNC that expressed NK cell marker CD56 did not significantly differ between subpopulations (Figure 4B). The proportions of NK cells (CD3nullCD56+) that expressed activation marker HLA-DR and Fc receptor CD16 were also nearly identical in these groups (Figure 4C).
**Cytotoxic Activity:** PBMNC of COPD and SC had similar cytotoxic activities at baseline and after incubation with IL-2, a nonspecific activator of NK cells and other lymphocytes (Figures 5A and 5B). However, stimulation with anti-KIR antibodies, to recapitulate *in vivo* engagements of lymphocyte KIR with HLA ligands, increased cytolytic activity of PBMNC cells from the COPD patients to a greater degree than that of the comparable SC preparations (Figure 5C).

The magnitude of cytolysis induced by *in vitro* KIR cross-linking was also inversely correlated with the pulmonary function of the individuals providing these specimens (Figure 5D). In contrast, PBMNC cytotoxicity at baseline and after nonspecific activation with IL-2 were not significantly association with pulmonary function (\(r=0.07, \ p=0.65\)) and (\(r=0.12, \ p=0.41\)), respectively.

To determine the subpopulation most responsible for cytotoxicity, analogous experiments were performed using either CD56\(^+\) (NK cells) or CD56\(^{null}\) subpopulations isolated from PBMNC, with their respective purities confirmed by flow cytometry (Online Supplement Figure 2). Intergroup comparisons showed the NK cells had much greater cytotoxic activity (Figure 6A).

Because the COPD associations of *HLA-C*\(^{*}07\) and *HLA-C*\(^{*}12\) were highly varied (Figures 1 and 2), even though both C1 allotypes nominally have similar KIR avidities (10-14), we hypothesized engagements of these alleles may, in fact, evoke different NK cell responses. Accordingly, we generated K562 target cells that expressed either one or the other of these HLA alleles and used these as targets in cytotoxic assays. We found K562 cells transfected with *HLA-C*\(^{*}07\) were more susceptible to NK cell cytolysis than either sham-transfected target cells or those that expressed *HLA-C*\(^{*}12\) (Figure 6B).
DISCUSSION

The present studies show certain immunoregulatory gene polymorphisms are highly associated with COPD susceptibility. In particular, HLA-C*07 was over-represented among COPD patients compared to smokers with normal pulmonary function (Figure 1A), whereas HLA-C*12 was conversely under-represented among the COPD (Figure 1B). Subsequent investigations revealed NK cell function-stimulating KIR2DS1 is also over-represented among COPD subjects (Figure 2B) and, moreover, effects conferred by this gene are interactive with both HLA-C*07 and HLA-C*12 alleles (Figures 2A-C). Stratifications to compare subjects with the highest risk haplotype (HLA-C*07 + KIR2DS1 + HLA-C*12null) vs. those with the lowest risk haplotype (HLA-C*12 + KIR2DS1null + HLA-C*07null) showed strong epistatic associations, especially among those who were homozygous for HLA-C1 allotypes (Figure 3C). Correlative functional assays showed KIR-mediated cytolysis is greatest in COPD patients (Figure 5C), significantly related to pulmonary physiology (Figure 5D), and enhanced among target cells that display HLA-C*07 compared to those expressing HLA-C*12 (Figure 6B). The present data support the concept that COPD pathogenesis results from a complex interplay between environmental agent(s) (e.g., tobacco smoke) and multiple genetic determinants (3,6). To the best of our knowledge, the series of findings presented here are unprecedented.

While the importance of immunological processes in COPD pathogenesis has long been appreciated (17), only a few studies have attempted to characterize HLA alleles among afflicted patients by use of specific, candidate gene assay methods (18-20). An early investigation used imprecise serologic typing to analyze a limited repertoire of HLA-A and -B alleles (many more alleles at each of these loci have since been discovered) and found HLA-B*07 was a susceptibility factor for COPD (18). That report may be concordant with the present data that also indicated a potential link between HLA-B*07 and COPD (Online Supplement Table 2), although we believe our finding is likely due to the very strong LD between this allele and HLA-C*07 (15). However, a later investigation, limited to an examination of HLA-B*07 among patients with relatively mild COPD, did not substantiate the initial report (19). More recently, analyses of HLA-Class II DR and DQ allele frequencies in a single
cohort study with 320 patients found over-representations of \textit{HLA-DRB1*14} in their COPD patients (20). The present study differs significantly from these earlier reports in several aspects, such as the use here of larger numbers of highly characterized subjects in extreme-of-phenotype comparisons, and prospective study of distinct replication cohorts. Moreover, we are unaware of any previous candidate gene analyses of HLA-C (or KIR) in COPD or attempts to link those genetic elements with immunological functions.

HLA and KIR typing by techniques that target these candidate genes, such as polymerase chain reaction amplifications using sequence-specific primers (PCR-SSP), are definitive, and may arguably be a method of choice for focused, finite pilot investigations (such as this study), but they are time-consuming, tedious, expensive, and utilize large amounts of precious specimen DNA. In contrast, high-throughput GWAS are facile and economical, especially in studies of large populations, and they concurrently identify many diverse disease-associated polymorphisms. Nonetheless, the study of HLA and KIR regions by GWAS can be problematic. The chromosomal regions for HLA (6p21) and KIR (19q13) are both characterized by unusually high gene densities, extreme polymorphism, and strong, nonrandom LD that complicate and confound GWAS imputations (21). Furthermore, discovery of synergistic (epistatic) interactions between disparate loci (e.g., HLA and KIR genes) may not be readily discerned by routine GWAS analyses. The COPD SNP variants identified by GWAS so far are also often associated with low-level risks that account for little of the heritance of this complex syndrome, and do not address phenotypic heterogeneity and disparate subject populations. In addition, the functional correlates of disease-associated variant SNPs, many of which are located in noncoding regions, may not be evident nor inform understandings of underlying pathological mechanisms. Despite inherent limitations, however, GWAS studies have found COPD associations with SNP in the region that includes HLA-C (22,23), and another disease susceptibility locus has been putatively identified in or proximate to the region encoding KIR (24,25).

The present findings are also concordant with studies that implicate NK cells in COPD pathogenesis (7,26-28). Although most previous reports find minimal differences of NK cell counts in
peripheral blood of COPD patients compared to controls (see also Figure 4) (29,30), subtle phenotypic alterations that associate with disease manifestations have also been described (26). Functional NK cell alterations, including increased activation and cytotoxic activity, as well as correlations between these altered functions and disease severity, have been found among COPD patients (29), and were also seen here (Figures 5C and 5D).

Although the pathological importance of HLA-KIR axis is recognized in many other syndromes (10-13,31,32), parsing out the nuances of this immunoregulatory mechanism is rendered difficult by many complexities and peculiarities. The net effect of the interactions mediated by the polymorphic KIR repertoire of any given NK cell depends on an integration of signals transduced from both function-inhibiting and function-stimulating receptors (10,32). Further confounding is introduced by the varied cell surface expression of the KIR per se, being unpredictably present in varying densities and proportions of cytotoxic effectors (33) [the extent of HLA-C surface expression on target cells is also often highly variable]. The lack of monoclonal antibodies with unique specificities for individual KIR hinders direct quantitation of these receptor expressions and assessments of their specific functions (34). Additional intricacies of this immunomodulatory process can arise from "education" of NK cells during their maturation, wherein engagements of their KIR with autologous, cognate HLA ligands lead to NK cell hypo-reactiveness (analogous to induction of peripheral tolerance in T-cells). KIR2DS1 is relatively unique among function-stimulating KIR in that it may variously be involved in both "education" and activation (35). KIR2DS1 binding affinity is nominally limited to HLA-C2 allotypes (10), in whom earlier "education" results in NK cell hypo-reactivity. Conversely, however, NK cell activity may be enhanced by the presence of KIR2DS1 among individuals who are C1/C2 heterozygotes, and even more so among C1 allotype homozygotes (Figure 3) (13,36). The findings in these COPD patients are very analogous to reports that have similarly shown the HLA-KIR combinations of importance seen here (Figs 1-3) are also associated with increased risks for the presence of other immunological syndromes (10-13,31).
This was an initial survey using a definitive, if cumbersome, methodology to test our hypothesis that HLA-Class I alleles may be associated with COPD susceptibility. This study was designed to identify biases [if present] among the most prevalent HLA-Class I [and KIR] that have especially strong associations with COPD, by comparing populations with extreme phenotypic differences (Table 1). The findings of this pilot trial justify further study with more detailed and thorough genetic analytical methodologies, such as Next Generation Sequencing (NGS) (37). In-depth studies of the COPD genetic “hotspots” localized here will further characterize the involvement of HLA and KIR in COPD by more precise identifications of the particular allelic variants with disease associations (there are 17 alleles of 2DS1 alone [13,38]). NGS studies could also possibly detect other genes within or close to the HLA and KIR loci that also contribute [if more weakly] to lung disease development and/or progression. In addition, the use of detailed high-throughput genetic analyses will expedite the incremental study of other demographic groups. The exclusive study of non-Hispanic whites in the present study limits the generalizability of these results since both HLA and KIR regions are associated with large differences between lineages (16,39).

The development of facile tests that accurately identify patients at heightened risk for COPD could have several important clinical applications, including enriched selections of subjects with the greatest disease predilections for expensive clinical trials, and personalized counseling and/or increased surveillances of especially at-risk individuals and their family members. Perhaps more importantly, better understanding of the pathological mechanisms of COPD might illuminate approaches for innovative therapies, and perhaps eventually guide the selection of biological response modifiers that specifically (and more effectively) target the causal processes of this recalcitrant lung disease.
METHODS

(see Online Supplement 1 for additional details)

Subjects: The initial COPD discovery cohort consisted of patients who underwent lung transplantation evaluations at the University of Pittsburgh Medical Center (UPMC) and had fixed expiratory airflow obstruction due to tobacco smoking. Discovery cohort Smoke Controls (SC) were participants in the UPMC Specialized Centers of Clinically Oriented Research registry (SCCOR) who had at least 30 pack-years of cigarette smoking, but normal spirometry.

Validation cohort subjects included Temple University Medical Center patients with severe airflow obstruction (i.e., GOLD Stage 3 or 4) (1), as well as consecutive SCCOR COPD participants. Validation SC subjects were recruited from the Pittsburgh Lung Screening Study registry at the Pittsburgh Cancer Institute. All validation participants fulfilled the inclusion and exclusion criteria of their respective discovery subpopulations. SCCOR participants (both COPD and SC) had high-resolution chest CT evaluations to evaluate emphysema (42).

Analyses were restricted to non-Hispanic whites because <5% of the initial discovery COPD lung transplantation cohort were members of minority groups, and HLA allele frequencies vary among racial/ethnic subpopulations (13,41).

HLA Typing: HLA were defined by analyses of leukocyte DNA using sequence-specific oligonucleotide probe assays, or PCR-SSP. These and other assays in this study were conducted by laboratory personnel who were blinded to subject identities and characteristics.

KIR Allele Typing: KIR genes were detected by PCR-SSP using methods previously published (41).

Cytotoxic Cell Assays: Peripheral blood mononuclear cells (PBMNC) were characterized by flow cytometry, using methods detailed elsewhere (42). PBMNC (effector cells) were used in cytotoxicity assays after two days treatment in either: 1) media control (baseline); 2) media supplemented with IL-2
at 6000 IU/ml; or 3) in wells pre-coated with mixtures of an anti-KIR monoclonal antibody cocktail. Cytolysis of K562 cells labeled with $^3$H-thymidine or calcein was detected by β-counter (42) or flow cytometry (43), respectively. In some cases, PBMNC were segregated prior to assays into CD56$^+$ and CD56$^{null}$ subpopulations using immunomagnetic beads and/or fluorescence-activated-cell-sorting (FACS).

**Target Cell HLA-C Transfections:** HLA-C*07 and HLA-C*12 were expressed in HLA$^{null}$ K562 target cells after cloning with a lentivirus construct system. PCR, sequencing, and flow cytometry confirmed successful HLA-C transfection and expression in the target cells. (Online Supplement Figure 3)

**Statistics:** HLA allele and KIR gene prevalences are described as the percentages of subjects with one or more copies of these genetic element(s). Intergroup comparisons of these genetic elements were made by Chi-square, with logistic regression used to generate odds ratios (OR) and confidence intervals (CI). Ordered and continuous variables were compared by Mann-Whitney rank-sum tests. Friedman tests were used to compare effects of multiple treatments in the same specimens. Associations between two continuous variables were examined by Pearson product-moment correlations. P values corrected for multiple comparisons by Bonferroni are denoted as $P_c$. $P$ (or $P_c$ if applicable) <0.05 were considered significant. Unless specified otherwise, data are depicted as means ± S.E.M. Data analyses were conducted by TM, YZ, YK, and SRD.

**Study Approval:** Written informed consent was received from all participants prior to inclusion in the study. Research protocols were approved by the Institutional Review Boards at the University of Pittsburgh, Temple University, and University of Alabama at Birmingham.
REFERENCES


**FIGURE LEGENDS**

**Figure 1.** *HLA-C*07 and *HLA-C*12 are Associated with COPD Prevalence.*  

A.) *HLA-C*07 is over-represented in the cumulative (discovery and validation) COPD cohort (n=392) compared to the Smoke Controls (SC) (n=342). Data are presented here (and elsewhere) as allele prevalence (the percentages of subjects with one or more copies of the allele). OR = odds ratio. CI = confidence interval.  

B.) *HLA-C*12 was under-represented in the SC, compared to the COPD subjects. Comparisons were made by Chi-square with determinations of OR and CI by logistic regression.
Figure 2. Interactive Associations of HLA-C*07 and HLA-C*12 with KIR2DS1 in COPD. A.) The prevalence of COPD among participants positive for both HLA-C*07 and KIR2DS1 (n=133) was significantly greater than in all the other subpopulations shown here. Analyses by Chi-square with Bonferroni corrections for multiple comparisons (Pc). B.) Conversely, the presence of HLA-C*12 in the absence of KIR2DS1 (n=46) appeared protective for COPD (Pc=comparisons of HLA-C*12 + KIR2DS1null vs. all other groups by Chi-square with Bonferroni corrections). C.) The association of COPD with the highest risk haplotype (HLA-C*07 and KIR2DS1 without HLA-C*12) was much greater than among subjects with the lowest risk haplotype (HLA-C*12 without either HLA-C*07 or KIR2DS1). SC denotes Smoke Controls. Comparisons were made by Chi-square with determinations of OR and CI by logistic regression.
Figure 3. COPD Associations with HLA-C Allotypes. A.) COPD prevalence was greatest in subjects homozygous for HLA C1 allotypes (n=307) (see Table 2) than among C1-C2 allotype heterozygotes (n=315), and least among those homozygous for C2 allotype alleles (n=116). Bars depict 95% CI and solid squares denote odds ratios for the presence of COPD. Analyses by Chi-square, with Bonferroni corrections for multiple comparisons. OR = odds ratios; CI = confidence intervals, as determined by logistic regression. B.) COPD associations with highest risk haplotype (HLA-C*07 + KIR2DS1 + HLA-C*12null) (n=123) vs. lowest risk haplotype (HLA-C*12 in the absence of either HLA-C*07 or KIR2DS1) (n=34) were less striking in C1-C2 allotype heterozygotes (n=315), compared to similar analyses of the entire subject population (Figure 2C). C.) COPD associations in highest risk vs. lowest risk haplotypes were especially strong among C1 homozygotes.
Figure 4. Cytotoxic Lymphocyte Phenotypes. A.) COPD and Smoke Control (SC) subjects (n=26 in each group) did not differ in the proportions of CD8 T-cells among their peripheral blood mononuclear cells (PBMNC) or CD8+CD56+ (putative NKT-cells). The lowest, second lowest, middle, second highest and highest lines represent 10th, 25th, 50th, 75th and 90th percentiles, respectively. The mean is denoted with a closed square. B.) There was a nonsignificant trend for larger proportions of CD3nullCD56+ (NK cells) among the PBMNC of the COPD subjects. C.) The extents of activation (HLA-DR+) and Fc receptor CD16 expression on NK cells (CD3nullCD56+) were similar in both subject populations. Comparisons were made by Mann-Whitney tests.
Figure 5. Activation of Cytotoxic Lymphocytes. A.) There were no differences of peripheral blood mononuclear cell (PBMNC) cytotoxic activity among Smoke Control (SC) and COPD specimens (n=21 each) at baseline (without ex vivo stimulation) or after incubation with IL-2 (B.) at varying ratios of effectors (PBMNC) to K562 targets (E:T Ratios). Data are depicted as means ± SE. Comparisons by Mann-Whitney. C.) In contrast, prior incubation of PBMNC with a cocktail of anti-KIR antibodies resulted in greater cytotoxicity among COPD specimens. Comparisons made by Mann-Whitney with Bonferroni corrections. D.) The maximal KIR-induced cytotoxicity (E:T=25) in these cumulative specimens was inversely correlated (by Spearman correlation coefficient) with forced expiratory volume in one second (FEV₁) as a percent of predicted normal values.
Figure 6. Differential Lymphocyte Cytotoxicity.  A) Cytolytic activity of peripheral blood mononuclear cells (PBMNC) depleted of NK cells (CD56<sup>null</sup>) was less than corresponding CD56<sup>+</sup> cells (NK cells) isolated from these PBMNC in every paired specimen (n=9). Effector (cytotoxic lymphocyte):Target (K562 cells) ratios ranging from 0.5 to 2.0 were tested (E:T ratios were identical between concomitant paired CD56<sup>null</sup> and CD56<sup>+</sup> coculture assays - connected by lines). Solid squares denote means and vertical lines are standard errors of the mean (S.E.M.). Comparisons by Mann-Whitney. B) PBMNC cytolysis of K562 cells that expressed HLA-C*07 (C07) after transfection (n=12) was much greater than K562 cells after mock transfections (Cnt) or among K562 cells that were transfected to express HLA-C*12 (C12) (n=12 in each group). E:T=ratios here were 20:1. Error bars represent S.E.M. Analyses by Friedman Statistic, with Student-Newman-Keuls for multiple comparisons.
**TABLES**

**Table 1. Clinical and Demographic Characteristics of the Aggregate Study Participants (both Discovery and Validation Cohorts)**

<table>
<thead>
<tr>
<th></th>
<th>Smoke Controls (SC)</th>
<th>COPD</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>342</td>
<td>392</td>
<td></td>
</tr>
<tr>
<td>Age (yr)</td>
<td>61 ± 7</td>
<td>63 ± 7</td>
<td>0.0005</td>
</tr>
<tr>
<td>% Males</td>
<td>57</td>
<td>54</td>
<td>0.39</td>
</tr>
<tr>
<td>Pack-years smoking</td>
<td>54 ± 21</td>
<td>58 ± 31</td>
<td>0.94</td>
</tr>
<tr>
<td>FEV₁%p</td>
<td>96 ± 11</td>
<td>31 ± 19</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>FEV₁/FVC</td>
<td>0.77 ± 0.04</td>
<td>0.36 ± 0.13</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>DLCO%p</td>
<td>82 ± 14*</td>
<td>39 ± 18</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>COPD Severity:</td>
<td></td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Mild (FEV₁ ≥ 80% predicted)</td>
<td>16 (4.1%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderate (50% ≤ FEV₁ ≤ 80% predicted)</td>
<td>34 (8.7%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Severe (30% ≤ FEV₁ ≤ 50% predicted)</td>
<td>103 (26.3%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Very Severe (FEV₁≤30% predicted)</td>
<td>239 (70.0%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

FEV₁ = forced expiratory volume in the first second of exhalation; FVC = forced vital capacity; DLCO = diffusing capacity for carbon monoxide; %p = percent of predicted normal values. Among SC, *DLCO were only measured in discovery cohort subjects (see Online Supplement 1). Comparisons were made by Mann-Whitney. COPD Severity categories are based on GOLD classifications in this disease (1). Data are denoted as means ± SD.
<table>
<thead>
<tr>
<th>Alleles (C1 or C2 Allotypes)</th>
<th>Smoke Control (n=342)</th>
<th>COPD (n=392)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>C*02 (C2)</td>
<td>11.7</td>
<td>8.9</td>
<td>0.22</td>
</tr>
<tr>
<td>C*03 (C1)</td>
<td>22.7</td>
<td>28.3</td>
<td>0.15</td>
</tr>
<tr>
<td>C*04 (C2)</td>
<td>26.0</td>
<td>17.9</td>
<td>0.04</td>
</tr>
<tr>
<td>C*05 (C2)</td>
<td>18.1</td>
<td>12.8</td>
<td>0.04</td>
</tr>
<tr>
<td>C*06 (C2)</td>
<td>18.1</td>
<td>15.8</td>
<td>0.40</td>
</tr>
<tr>
<td>C*07 (C1)</td>
<td>45.0</td>
<td>62.0</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>C*12 (C1)</td>
<td>13.7</td>
<td>7.1</td>
<td>0.003</td>
</tr>
</tbody>
</table>

HLA-C allele prevalences (the percentages of subjects with one or more copies of the allele) in the entire COPD population compared to all Smoke Control (SC) subjects. Only alleles with prevalences >10% in the normal subjects are shown here. Comparisons made by Chi-square. None of the intergroup comparisons among those infrequent alleles (not shown here) approached statistical significance.